lncRNA PICART1 alleviates progression of cervical cancer by upregulating TCF21

Introduction

Cervical cancer (CC) is a prevelant female malignancy with a high mortality. In 2012, there were 527,600 newly onset cases and 265,700 death cases globally (1). With advance in the screening technologies and therapeutic strategies, the incidence and mortality of CC are on the decline (2). Nevertheless, the overall survival of CC patients is poor (3). Effective hallmarks that predict the occurrence and progression of CC are lacking. Currently, squamous cell carcinoma antigen (SCC-Ag) is commonly applied for diagnosing CC (4). However, the sensitivity and specificity of SCC-Ag are relatively low, which markedly restricts its clinical application. It is necessary and urgent to uncover efficient diagnostic markers for CC.

Long non-coding RNAs (lncRNAs) are widely expressed in mammals and regulate gene expression. They are able to mediate various cellular behavior (5,6). lncRNAs influence the occurrence and progression of tumors as oncogenes or tumor-suppressor genes (7). It is reported that lncRNAs form different types of complexes alongside many factors, thus directly regulating downstream genes and affecting malignant phenotypes of tumor cells (8). Several abnormally expressed lncRNAs have been identified in CC. These lncRNAs may be utilized as diagnostic and prognostic hallmarks (9). In this study, we explored the biological function of lncRNA PICART1 in the malignant progression of CC and the potential mechanism.

Patients and methods

Sample collection and ethical statements

Sixty paired CC tissues and paracancerous tissues were surgically harvested from CC patients admitted to Weifang People's Hospital (Weifang, China) from March 2016 to October 2018. Tumor node metastasis (TNM) staging and tumor size of enrolled CC patients were recorded. None of these patients were preoperatively treated. This study was approved by the Medical Ethics Committee of Weifang People's Hospital and informed consent was received from each subject.

RNA extraction and qRT-PCR

Cells and tissues were lysed using TRIzol method (Invitrogen; Thermo Fisher Scientific, Inc.) for reverse transcription of RNAs using the PrimeScript RT reagent Kit (Takara). RNA was quantified using spectrometer and subjected to qRT-PCR following SYBR Premix Ex Taq™ (Takara). Relative level of target gene was determined by the 2−∆∆ct method.

Cell culture and transfection

CC cell lines (HeLa, C4-1, SiHa, Caski) and normal cervical endothelial cell line (Etc1/E6E7) were obtained from American Type Culture Collection (ATCC) (Manassas). Cell culture was conducted using Roswell Park Memorial Institute 1640 (RPMI-1640) medium (HyClone; GE Healthcare) with 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.) in an incubator with 5% CO2 at 37°C. For cell transfection, 1.5 ml of serum-free medium and 0.5 ml of Lipofectamine™ 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) containing transfection vectors were applied in each well of a 6-well plate. Fresh medium was replaced 4–6 h later. Transfected cells for 24–48 h were collected for determination.

Cell Counting Kit-8 (CCK-8) assay

Cell density was adjusted to 2×103 cells/100 µl and cells were inoculated in a 96-well plate. At the appointed times, cells per well were incubated with 10 µl of CCK-8 solution (CCK-8, Dojindo Molecular Technologies, Inc.). Absorbance (450 nm) was recorded by a microplate reader (Bio-Rad Laboratories, Inc.).

Transwell assay

Suspension (1.0×105 cells/ml) was prepared and subjected to serum starvation for 12 h. Suspension (200 µl/well) was applied in the upper side of Transwell chamber (EMD Millipore) pre-coated with Matrigel. In the lower side, 700 µl of medium containing 10% FBS was applied. After 48 h of incubation, cells invaded to the lower side were subjected to fixation in methanol for 15 min, crystal violet staining for 20 min and cell counting using a microscope. Invasive cells were counted in 5 randomly selected fields per sample. Migration assay was performed in the same way except for Matrigel pre-coating.

Determination of subcellular distribution

Cytoplasmic and nuclear RNAs were extracted using the PARIS kit (Invitrogen; Thermo Fisher Scientific, Inc.) and subjected to qRT-PCR. U6 was the internal reference of nucleus and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was that of cytoplasm.

RNA immunoprecipitation (RIP)

Cells were treated according to the procedures of Millipore Magna RIP™ RNA-Binding Protein Immunoprecipitation kit (EMD Millipore). Cell lysate was incubated with antibodies or anti-IgG antibody at 4°C for 6 h. A protein-RNA complex was captured and digested with 0.5 mg/ml proteinase K containing 0.1% sodium dodecyl sulphate (SDS) to extract RNA. The magnetic beads were repeatedly washed with RIP washing buffer to remove non-specific adsorption as much as possible. Finally, the extracted RNA was subjected to mRNA level determination using qRT-PCR.

Chromatin immunoprecipitation (ChIP)

Cells were subjected to cross-link with 1% formaldehyde at room temperature for 10 min into small fractions with 200–300 bp. Subsequently, cells were lysed and sonicated for 30 min. Finally, the sonicated lysate was immuno-precipitated with anti-TCF21, anti-ARID1A or anti-IgG. Purified immunoprecipitated chromatins were subjected to qRT-PCR.

Western blotting

Cells were lysed using radioimmunoprecipitation assay (RIPA) and extracted protein was quantified by bicinchoninic acid (BCA) method (Beyotime Institute of Biotechnology). Electrophoresis was conducted for transferring proteins on a polyvinylidene fluoride (PVDF) membranes (EMD Millipore). After 2-h blockage of non-specific sites in 5% skim milk, membranes were reacted with primary and secondary antibodies. Band exposure was achieved by electrochemiluminescence (ECL) and analyzed by Image Software (National Institutes of Health).

Statistical analysis

Statistical Product and Service Solutions (SPSS) 22.0 statistical software (IBM Corp.) was used for data analysis. Data were expressed as mean ± standard deviation (mean ± SD). Intergroup data were compared using the t-test. Kaplan-Meier curves were employed for survival analysis. Pearson's correlation analysis was conducted for evaluating the relationship between two genes. P<0.05 was considered to indicate a statistically significant difference.

Results

PICART1 is downregulated in CC

Expression level of PICART1 was determined in 60 paired CC tissues. PICART1 was downregulated in CC tissues relative to paracancerous ones (Fig. 1A). Identically, its level remained lower in CC cell lines than that of normal cervical endothelial cell line (Fig. 1B). PICART1 was found to be closely related to clinical characteristics of CC patients. Relative to CC patients in stage I+II, those in stage III+IV presented lower level of PICART1 (Fig. 1C). Lower abundance of PICART1 was observed in CC tissues larger than 4 cm in tumor size (Fig. 1D). Survival analysis showed worse prognosis in CC patients with low level of PICART1 (Fig. 1E).

Figure 1. PICART1 is downregulated in CC. (A) Relative level of PICART1 in cervical cancer tissues and paracancerous tissues. PT, paracancerous tissues; CC, cervical cancer. (B) Relative level of PICART1 in cervical cancer cell lines (HeLa, C4-1, SiHa, Caski) and normal cervical endothelial cell line (Etc1/E6E7). (C) Relative level of PICART1 in cervical cancer patients with stage I+II and III+IV. (D) Relative level of PICART1 in cervical cancer tissues ≤4 cm and >4 cm in tumor size. (E) Kaplan-Meier curves were introduced for assessing the overall survival in cervical cancer patients with high level and low level of PICART1. *P<0.05.

Silence of PICART1 accelerates proliferative, migratory and invasive abilities of CC

We constructed si-PICART1 and tested its transfection efficacy. Transfection of si-PICART1 greatly downregulated PICART1 level in HeLa and SiHa cells (Fig. 2A). The viability in CC cells was markedly elevated after silence of PICART1 (Fig. 2B and C). Similarly, the migratory and invasive abilities of CC cells were accelerated after transfection of si-PICART1 (Fig. 2D and E).

Figure 2. Silence of PICART1 accelerates proliferative, migratory and invasive abilities of CC. (A) Transfection efficacy of si-PICART1 in HeLa and SiHa cells. (B) CCK-8 assay showed viability in HeLa cells transfected with si-NC or si-PICART1. (C) CCK-8 assay showed viability in SiHa cells transfected with si-NC or si-PICART1. (D) Transwell assay shows the migration in HeLa and SiHa cells transfected with si-NC or si-PICART1. (E) Transwell assay shows the invasion in HeLa and SiHa cells transfected with si-NC or si-PICART1. CCK-8, Cell Counting Kit-8. *P<0.05.

PICART1 positively regulates TCF21 level

Compared with paracancerous tissues, TCF21 expression was low in CC tissues (Fig. 3A). A positive correlation between expression levels of TCF21 and PICART1 was observed in CC tissues (R2=0.236, P<0.001, Fig. 3B). Transfection of si-PICART1 downregulated both mRNA and protein level of TCF21 in HeLa and SiHa cells (Fig. 3C). Kaplan-Meier curves revealed worse prognosis in CC patients expressing low level of TCF21 (Fig. 3D). It is believed that TCF21 is closely related to the malignant progression of CC.

Figure 3. PICART1 positively regulates TCF21 level. (A) Relative level of TCF21 in cervical cancer tissues and paracancerous tissues. (B) A positive correlation between expression levels of TCF21 and PICART1 in CC tissues (R2=0.236, P<0.001). (C) Relative level of TCF21 in HeLa and SiHa cells transfected with si-NC or si-PICART1. (D) Kaplan-Meier curves introduced for assessing the overall survival in cervical cancer patients with high level and low level of TCF21. PT, paracancerous tissues; CC, cervical cancer. *P<0.05.

PICART1 recruites ARID1A to activate TCF21 expression

Subcellar distribution analysis showed that PICART1 was mainly expressed in nuclear fraction of HeLa cells (Fig. 4A). We next explored the possible functions of PICART1 and TCF21 in the progression of CC. Analysis of the DNA sequences in TCF21 promoter region showed a remarkable enrichment of PICART1 from −1000 to −500 bp (Fig. 4B). Moreover, the interaction between PICART1 and ARID1A was also identified (Fig. 4C and D). Potential binding sites were verified among PICART, ARID1A and TCF21. ChIP assay confirmed the decreased enrichment of ARID1A in TCF21 promoter region after PICART1 knockdown (Fig. 4E and F).

Figure 4. PICART1 recruites ARID1A to activate TCF21 expression. (A) Subcellular distribution of PICART1 in nuclear and cytoplasmic fraction of HeLa cells. U6 is the nuclear internal reference and GAPDH is that of the cytoplasm. (B) Enrichment of PICART1 in TCF21 promoter region. (C) Enrichment of PICART1 in anti-IgG and anti-ARID1A in HeLa and SiHa cells. (D) Relative level of ARID1A in PICART1 promoter region. (E) Enrichment of TCF21 in anti-IgG and anti-ARID1A in HeLa and SiHa cells. (F) Relative level of TCF21 in HeLa and SiHa cells transfected with si-NC or si-PICART1. *P<0.05.

Discussion

CC ranks fourth in the morbidity and mortality of malignant tumors throughout the world. The prognosis of CC is unsatisfactory. Many genes, factors and pathways are involved in tumorigenesis of CC. It is of great significance to seek effective diagnostic and prognostic markers for CC.

A large number of observational studies have been conducted to identify the potential role of lncRNAs related to CC. For example, serum level of lncRNA PVT1 is upregulated in CC patients, which exerts diagnostic potential with 71.6 sensitivity and 98.8% specificity (10). lncRNA XLOC_010588 is downregulated in CC patients and predicts poor prognosis (11). In this study, lncRNA PICART1 was downregulated in CC tissues and cell lines. Silence of PICART1 accelerated the proliferative, migratory and invasive abilities of HeLa and SiHa cells.

TCF21 was found to be the target gene of PICART1. TCF21, also known as Pod-1, capsuling and epicardin, mediates cell differentiation and apoptosis by binding to DNAs in the developmental process (12). TCF21 is mainly expressed in the embryonic mesenchymal cells around the kidney, heart, lung and gastrointestinal epithelial developmental areas (13,14). Its level rapidly decreases after birth except for that in kidney, heart, lung and spleen stromal cells (15). Antisense inhibition of TCF21 has been reported to disrupt epithelial differentiation and branching morphogenesis in epithelial cells in mouse embryonic kidneys, suggesting that TCF21 could influence the process of EMT (16). TCF21 deficiency in the kidney results in decreased glomerulogenesis and tubular formation (17). Notably, transfection of TCF21 siRNA in mesenchymal progenitor cells from mouse kidney stimulates proliferative and migratory abilities, as well as downregulates expression of smooth muscle and myofibroblast secreted proteins (15). In clinical trials, ARID1A mutation is believed to be closely related to poor prognosis of ovarian cancer patients, indicating its tumor-suppressor role (18,19). ARID1A protects genomic stability and antagonizes the carcinogenic role of EZH2 in clear cell carcinoma of ovary (20,21). In addition, ARID1A as a priority guides SWI/SNF complexes H3K27ac- and H3K4me1-labeled enhancers to interact with multiple transcriptional factors (22). Owing to the dislocation of SWI/SNF complexes to enhancers, ARID1A deficiency astimulates the progression of adenocarcinoma of colon in mice. Herein, our study found that PICART1 recruited ARID1A to activate TCF21 expression, thus alleviating the progression of CC. It is noteworthy that PICART1 shows ability to mediate a series of downstream genes. RNA sequencing of downstream targets after silencing of PICART1 is necessary.

In conclusion, lncRNA PICART1 is downregulated in CC tissues, and closely related to disease progression. PICART1 recruits ARID1A to activate TCF21 expression, thus alleviating the malignant progression of cervical cancer. It is believed that PICART1 may be utilized as a new drug target for CC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

YZ and RH designed the study and performed the experiments, YZ and XD collected the data, RH and XD analyzed the data, YZ and RH prepared the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Weifang People's Hospital (Weifang, China). Signed informed consents were obtained from the patients and/or the guardians.

Patients consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References